Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, ...

The European stock markets were tracking lower in Friday ... addressing Alzheimer's care and may be a factor behind Eli Lilly's 4% price rise over the last quarter. Other significant developments ...

These Chinese companies are also in a position to assign a lower price to these medicines compared ... supporting bullish sentiments for the stock. On February 10, the company announced a ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

All of this has helped Lilly's revenue climb in the double digits in recent quarters and the stock price to take off. The shares have advanced more than 200% over the past three years. Now the ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...